JMP Securities Remains a Hold on Incyte Corp (INCY)

In a report issued on February 7, Liisa Bayko from JMP Securities maintained a Hold rating on Incyte Corp (INCY). The company’s shares closed on Friday at $80.87.

According to TipRanks.com, Bayko is a 5-star analyst with an average return of 15.6% and a 45.1% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Enanta Pharmaceuticals, and Aimmune Therapeutics.

Currently, the analyst consensus on Incyte Corp is a Moderate Buy with an average price target of $90.11, an 11.4% upside from current levels. In a report issued on February 4, Cantor Fitzgerald also reiterated a Hold rating on the stock with a $74 price target.

See today’s analyst top recommended stocks >>

Based on Incyte Corp’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $29.18 million. In comparison, last year the company had a GAAP net loss of $150 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.